PATENT CLAIM ANALYSIS

Application Number: 16386915
Application Type: Utility
Filing Date: 2019-04
Publication Date: 2019-09
Patent Classification: ["514", "047000"]

Abstract:
The invention relates generally to a pharmacological therapy for a human genetic diseases, specifically mitochondrial DNA depletion syndromes, and more specifically, thymidine kinase 2 (TK2) deficiency. The pharmacological therapy involves the administration of at least one deoxyribonucleoside monophosphate, or mixtures thereof. For the treatment of TK2 deficiency, the pharmacological therapy involves the administration of either deoxythymidine monophosphate (dTMP) or deoxycytidine monophosphate (dCMP), or mixtures thereof. This molecular bypass approach is applicable to other disorders of unbalanced nucleotide pools, especially those found in mitochondrial DNA depletion syndrome.

Claim (Index 17):
The method of  claim 12 , wherein the composition comprises more than one deoxyribonucleoside monophosphate and the therapeutically effective amount is between about 200 mg/kg/day and about 800 mg/kg/day of the total deoxyribonucleoside monophosphates in the composition.

Metadata:
- Claim Count in Document: 57.0
- Percentile: 100.0
- Lexical Diversity: 1.63492
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15082207', '15736092', '12205588', '14656096', '15218790']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7532117963869137
- 35 USC 102 Novelty (BERT): 0.6711139820446482
- Combined Prediction Score: 0.7450020149526873
- Mean Citation Score: 405.63436399999983
- Max Citation Score: 810.0359
- Similarity Product: 604.49501467731

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test